Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Current and future burden from Lyme disease in Qu ébec as a result of climate change
CONCLUSION: The epidemiological burden is concentrated primarily in southern Québec, but the clinical and economic burden is already distributed throughout the province. The projections for 2050 should help the regions of Québec adapt and optimize public health protection measures.PMID:38481649 | PMC:PMC10937046 | DOI:10.14745/ccdr.v49i10a06 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Marion Ripoche Alexandra Irace-Cima Ariane Adam-Poupart Genevi ève Baron Catherine Bouchard Alex Carignan Fran çois Milord Najwa Ouhoummane Pierre A Pilon Karine Thivierge Kate Zinszer Diane Chaumont Source Type: research
Healthcare costs and effects of post-COVID-19 condition in Canada
CONCLUSION: This article demonstrates the large potential health and economic burden of PCC for Canadians, and the importance of vaccination and other infection control strategies in reducing the longer-term costs and effects.PMID:38481650 | PMC:PMC10936747 | DOI:10.14745/ccdr.v49i10a03 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Ellen Rafferty Ali Unsal Erin Kirwin Institute of Health Economics Edmonton Department of Medicine Faculty of Medicine and Dentistry University of Alberta Edmonton Health Organisation Policy Economics School of Health Sciences University of Manchester Man Source Type: research
Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community
The objective of this short commentary is to alert the Canadian public health community and to provide information that could be used at the field level to promote the usefulness of influenza vaccines.PMID:38481651 | PMC:PMC10936748 | DOI:10.14745/ccdr.v49i10a04 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Philippe De Wals Micha ël Desjardins Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Current and future burden from Lyme disease in Qu ébec as a result of climate change
CONCLUSION: The epidemiological burden is concentrated primarily in southern Québec, but the clinical and economic burden is already distributed throughout the province. The projections for 2050 should help the regions of Québec adapt and optimize public health protection measures.PMID:38481649 | PMC:PMC10937046 | DOI:10.14745/ccdr.v49i10a06 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Marion Ripoche Alexandra Irace-Cima Ariane Adam-Poupart Genevi ève Baron Catherine Bouchard Alex Carignan Fran çois Milord Najwa Ouhoummane Pierre A Pilon Karine Thivierge Kate Zinszer Diane Chaumont Source Type: research
Healthcare costs and effects of post-COVID-19 condition in Canada
CONCLUSION: This article demonstrates the large potential health and economic burden of PCC for Canadians, and the importance of vaccination and other infection control strategies in reducing the longer-term costs and effects.PMID:38481650 | PMC:PMC10936747 | DOI:10.14745/ccdr.v49i10a03 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Ellen Rafferty Ali Unsal Erin Kirwin Institute of Health Economics Edmonton Department of Medicine Faculty of Medicine and Dentistry University of Alberta Edmonton Health Organisation Policy Economics School of Health Sciences University of Manchester Man Source Type: research
Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community
The objective of this short commentary is to alert the Canadian public health community and to provide information that could be used at the field level to promote the usefulness of influenza vaccines.PMID:38481651 | PMC:PMC10936748 | DOI:10.14745/ccdr.v49i10a04 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Philippe De Wals Micha ël Desjardins Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
National Influenza Annual Report, Canada, 2022-2023: Canada's first fall epidemic since the 2019-2020 season
Can Commun Dis Rep. 2023 Oct 1;49(10):413-424. doi: 10.14745/ccdr.v49i10a02. eCollection 2023 Oct 1.ABSTRACTCoinciding with the beginning of the coronavirus disease 2019 (COVID-19) pandemic in March 2020, Canadian seasonal influenza circulation was suppressed, which was a trend reported globally. Canada saw a brief and delayed return of community influenza circulation during the spring of the 2021-2022 influenza season. Surveillance for Canada's 2022-2023 seasonal influenza epidemic began in epidemiological week 35 (week starting August 28, 2022) and ended in epidemiological week 34 (week ending August 26, 2023). The 2022-...
Source: Can Commun Dis Rep - March 13, 2024 Category: Infectious Diseases Authors: Kara Schmidt Myriam Ben Moussa Steven Buckrell Abbas Rahal Taeyo Chestley Nathalie Bastien Liza Lee Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024
CONCLUSION: Overall, NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to all individuals aged six months and older who do not have a contraindication to the vaccine, with particular focus on the groups for whom influenza vaccination is particularly recommended.PMID:38476927 | PMC:PMC10927251 | DOI:10.14745/ccdr.v49i10a01 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 13, 2024 Category: Infectious Diseases Authors: Angela Sinilaite Winnie Siu Jesse Papenburg Source Type: research
National Influenza Annual Report, Canada, 2022-2023: Canada's first fall epidemic since the 2019-2020 season
Can Commun Dis Rep. 2023 Oct 1;49(10):413-424. doi: 10.14745/ccdr.v49i10a02. eCollection 2023 Oct 1.ABSTRACTCoinciding with the beginning of the coronavirus disease 2019 (COVID-19) pandemic in March 2020, Canadian seasonal influenza circulation was suppressed, which was a trend reported globally. Canada saw a brief and delayed return of community influenza circulation during the spring of the 2021-2022 influenza season. Surveillance for Canada's 2022-2023 seasonal influenza epidemic began in epidemiological week 35 (week starting August 28, 2022) and ended in epidemiological week 34 (week ending August 26, 2023). The 2022-...
Source: Can Commun Dis Rep - March 13, 2024 Category: Infectious Diseases Authors: Kara Schmidt Myriam Ben Moussa Steven Buckrell Abbas Rahal Taeyo Chestley Nathalie Bastien Liza Lee Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024
CONCLUSION: Overall, NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to all individuals aged six months and older who do not have a contraindication to the vaccine, with particular focus on the groups for whom influenza vaccination is particularly recommended.PMID:38476927 | PMC:PMC10927251 | DOI:10.14745/ccdr.v49i10a01 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 13, 2024 Category: Infectious Diseases Authors: Angela Sinilaite Winnie Siu Jesse Papenburg Source Type: research
A Pediatric Investigators Collaborative Network on Infections in Children (PICNIC) multi-centre Canadian descriptive analysis of < em > Haemophilus influenzae < /em > bacteremia in children: Emerging serotypes
CONCLUSION: In the era of efficacious conjugate Hib vaccines, NTHi, Hia and Hif have emerged as the leading causes of invasive Hi in Canadian children, with Hia being most likely to result in meningitis and complicated disease. A vaccine for all NTHi and THi would be ideal, but knowledge of the current disease burden from circulating strains will inform prioritization of vaccine targets.PMID:38463901 | PMC:PMC10919449 | DOI:10.14745/ccdr.v49i09a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 11, 2024 Category: Infectious Diseases Authors: Craig Frankel Joan Robinson Sarah Khan Mohammad Alghounaim Jane McDonald Alison Lopez Sergio Fanella John Gunawan Jacqueline Wong Jeannette Comeau Jennifer Bowes Robert Slinger Angela Kalia Ashley Roberts Kirk Leifso Marina Ulanova Michelle Barton Source Type: research
Antimicrobial susceptibilities of < em > Neisseria gonorrhoeae < /em > in Canada, 2021
CONCLUSION: The spread of antimicrobial-resistant gonorrhea is a significant public health concern. The continued regional and national surveillance of antimicrobial resistance in N. gonorrhoeae is essential in ensuring effective treatment therapies are recommended.PMID:38463902 | PMC:PMC10919915 | DOI:10.14745/ccdr.v49i09a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 11, 2024 Category: Infectious Diseases Authors: Pamela Sawatzky Brigitte Lefebvre Mathew Diggle Linda Hoang Jason Wong Samir Patel Paul Van Caessele Jessica Minion Richard Garceau Sarah Jeffrey David Haldane Lillian Lourenco Genevieve Gravel Michael Mulvey Irene Martin Source Type: research
